Reply to the Letter to the Editor 'Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval?' by Y. Sasaki; E. Sato & C. Sakaguchi

Ann Oncol. 2022 Oct;33(10):1083-1084. doi: 10.1016/j.annonc.2022.06.006. Epub 2022 Jun 27.

Authors

J Tanizaki¹, K Nakagawa¹, H Hayashi²

Affiliations

¹ Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
² Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. Electronic address: hidet31@med.kindai.ac.jp.

PMID: 35772666
DOI: 10.1016/j.annonc.2022.06.006

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Comment

MeSH terms

Humans
Neoplasms, Unknown Primary* / drug therapy
Nivolumab* / adverse effects

Substances

Nivolumab